Ablin R J, Marrow C, Guinan P D, Bruns G R, Sadoughi N, John T, Bush I M
Urol Int. 1976;31(6):444-58. doi: 10.1159/000280080.
Host cellular responsiveness to tumour was evaluted in 37 patients with varying degrees of clinically active and inactive adenocarcinoma of the prostate by direct inhibition of leucocyte migration (ILM) employing saline extracts of pooled allogeneic normal, benign and malignant prostatic tissue as a source of antigen. The majority of these patients had received or were receiving conventional therapy at the time of evaluation. 13 (35%) prostatic cancer patients possessed clinically significant specific reactivity to malignant prostatic tissue, whereas only 1 (8%), of 13 control patients (11 healthy adults and 2 patients with carcinoma other than of the prostate: bladder and penis) possessed comparable reactivity. While the wide range of specific reactivity observed overall, including 'stimulation' of migration, compared with the mean percent ILM was very large, the SD of the mean specific percent ILM in the 13 prostatic cancer patients possessing clinically significant specific reactivity to malignant prostatic tissue, was most respectable. Since all reactions were allogeneic, these results indicated that prostatic cancer patients possessed cell-mediated immunity to presumably common prostatic tumour-associated antigens. Further evaluation disclosed that the incidence of patients possessing clinically significant reactivity to malignant tissue was almost identical regardless of the patient's stage of malignancy, histological grade of tumour, or clinical status. The degree of sensitization of clinically significant reactivity to malignant tissue was, however, greater in patients with localized disease, low grade tumour, and clinically inactive disease, than in patients with advanced disease, high-grade tumour, and clinically active disease. Evaluation of the possible correlation of specific reactivity to malignant prostatic tissue as a prognostic index of subsequent clinical responsiveness revealed a positive correlation with the degree of sensitization in 3 (43%) of 7 patients available for routine follow-up. Correlation in four patients was questionable due to the observations of 'stimulation' of migration rather than inhibition. While providing initial preliminary evidence of the presence of cell-mediated anti-tumour immunity in patients with prostatic cancer and promise of a possible prognostic index, the wide range in the variability of cellular responsiveness and the failure to identify clinically significant reactivity to malignant prostatic tissue in the majority (65%) of the patients evaluated, raises concern as to whether ILM employing saline extracts will provide the necessary in vitro assay of cellular responsivenss for the evaluation of prostatic cancer patients.
通过采用同种异体正常前列腺组织、良性前列腺组织和恶性前列腺组织的盐水提取物作为抗原来源，直接抑制白细胞迁移（ILM），评估了37例不同程度临床活动期和非活动期前列腺腺癌患者机体对肿瘤的细胞反应性。在评估时，这些患者中的大多数已经接受或正在接受传统治疗。13例（35%）前列腺癌患者对恶性前列腺组织具有临床上显著的特异性反应，而13例对照患者（11名健康成年人和2例前列腺以外的癌症患者：膀胱癌和阴茎癌）中只有1例（8%）具有类似反应。虽然总体观察到的特异性反应范围很广，包括与平均白细胞迁移抑制率（ILM）相比的迁移“刺激”，但在对恶性前列腺组织具有临床上显著特异性反应的13例前列腺癌患者中，平均特异性ILM百分比的标准差是相当可观的。由于所有反应都是同种异体的，这些结果表明前列腺癌患者对可能常见的前列腺肿瘤相关抗原具有细胞介导的免疫力。进一步评估发现，无论患者的恶性肿瘤分期、肿瘤组织学分级或临床状态如何，对恶性组织具有临床上显著反应性的患者发生率几乎相同。然而，与晚期疾病、高分级肿瘤和临床活动期疾病患者相比，局限性疾病、低分级肿瘤和临床非活动期疾病患者对恶性组织的临床显著反应性的致敏程度更高。将对恶性前列腺组织的特异性反应性作为后续临床反应性的预后指标进行可能相关性评估，发现在7例可进行常规随访的患者中，有3例（43%）与致敏程度呈正相关。由于观察到迁移“刺激”而非抑制，4例患者的相关性存在疑问。虽然为前列腺癌患者存在细胞介导的抗肿瘤免疫提供了初步证据，并有望成为一种可能的预后指标，但细胞反应性变异性的广泛范围以及在大多数（65%）评估患者中未能识别出对恶性前列腺组织的临床上显著反应性，引发了人们对采用盐水提取物的白细胞迁移抑制试验是否能为评估前列腺癌患者提供必要的细胞反应性体外检测方法的担忧。
